Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junín virus.
Arenavirus
Argentine haemorrhagic fever
Glycoprotein 1
Horse antiserum
Junín virus
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
17
07
2019
revised:
18
11
2019
accepted:
20
11
2019
pubmed:
25
11
2019
medline:
1
12
2020
entrez:
25
11
2019
Statut:
ppublish
Résumé
Argentine haemorrhagic fever (AHF) is a rodent-borne disease with a lethality as high as ~30%, which is caused by the New World arenavirus, Junín virus (JUNV). It was once a major epidemic in South America and puts millions of people in Argentina at risk. Here, we aimed to develop horse antibodies or antibody fragments against JUNV. Before preparing the horse antibodies, a strategy to efficiently generate horse antisera was established based on comparisons among immunogens and immunization methods in both mice and horses. Antisera against JUNV were finally obtained by vaccinating horses with vesicular stomatitis virus pseudotypes bearing JUNV GP. The horse antibodies IgG and F(ab')
Identifiants
pubmed: 31760108
pii: S0166-3542(19)30401-2
doi: 10.1016/j.antiviral.2019.104666
pmc: PMC7114285
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin Fragments
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104666Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no competing financial interests.
Références
J Virol. 2006 Feb;80(3):1340-51
pubmed: 16415011
J Virol. 2018 Jul 31;92(16):
pubmed: 29899092
Expert Rev Vaccines. 2012 Feb;11(2):189-209
pubmed: 22309668
PLoS Negl Trop Dis. 2016 Jan 05;10(1):e0004325
pubmed: 26730709
Antiviral Res. 2017 Jan;137:125-130
pubmed: 27890674
J Virol. 2016 Jan 20;90(7):3515-29
pubmed: 26792737
Clin Exp Vaccine Res. 2015 Jan;4(1):1-10
pubmed: 25648133
J Virol. 2019 Feb 19;93(5):
pubmed: 30541860
Curr Opin Virol. 2019 Feb;34:18-28
pubmed: 30497052
Acta Pharmacol Sin. 2005 Dec;26(12):1479-84
pubmed: 16297347
Sci Rep. 2016 Apr 12;6:24179
pubmed: 27067649
J Virol Methods. 2010 Nov;169(2):365-74
pubmed: 20709108
Presse Med. 1986 Dec 20;15(45):2239-42
pubmed: 2949253
J Infect Dis. 1998 Feb;177(2):277-83
pubmed: 9466512
Nat Commun. 2016 May 10;7:11544
pubmed: 27161536
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2664-9
pubmed: 18268337
Methods Mol Biol. 2018;1604:3-31
pubmed: 28986822
Cell Host Microbe. 2017 Oct 11;22(4):471-483.e5
pubmed: 28966056
Viruses. 2016 Dec 18;8(12):
pubmed: 27999340
Microb Pathog. 1990 Oct;9(4):219-26
pubmed: 1965845
J Virol. 2004 May;78(10):5458-65
pubmed: 15113924
mSphere. 2018 May 2;3(3):
pubmed: 29720525
Annu Rev Pathol. 2013 Jan 24;8:411-40
pubmed: 23121052
Nature. 2007 Mar 1;446(7131):92-6
pubmed: 17287727
PLoS Negl Trop Dis. 2016 Apr 08;10(4):e0004565
pubmed: 27058956
Viruses. 2012 Jan;4(1):83-101
pubmed: 22355453
Cell Host Microbe. 2015 Dec 9;18(6):705-13
pubmed: 26651946
Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7031-7036
pubmed: 28630325
J Gen Virol. 2014 Jan;95(Pt 1):1-15
pubmed: 24068704
Nat Commun. 2018 May 14;9(1):1884
pubmed: 29760382
Antiviral Res. 2018 Aug;156:21-28
pubmed: 29870772
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4458-63
pubmed: 27044104
Virol Sin. 2016 Oct;31(5):380-394
pubmed: 27562602
Respir Res. 2006 Mar 23;7:43
pubmed: 16553963
Antiviral Res. 2008 Apr;78(1):132-9
pubmed: 18054395
Sci Rep. 2018 Jul 30;8(1):11451
pubmed: 30061671
Cell Host Microbe. 2009 Oct 22;6(4):381-91
pubmed: 19837377
Curr Top Microbiol Immunol. 2007;315:253-88
pubmed: 17848068